A precipitous step deeper into the CDMO business
23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."
Pages
52
Language
English
Published on
23/11/20
You may also be interested by these reports :
28/09/26
BASF is looking to consolidate its lead in chemicals by acquiring Evonik. The appeal lies in portfolio adjacency, principally in Materials and ...
23/09/26
Johnson Matthey (UK, Reduce) has spent the past few years doing what many industrial conglomerates eventually do: shedding parts of itself until only ...
23/09/26
Weak FY25/26 results (below expectations) – Solid outlook on FY26/27E
08/09/26
Wacker’s polysilicon business has been under pressure for years now, given Chinese overcapacity. Semis have been the growth engine, partly offsetting ...